VOCINTI Vonoprazan 10mg Film-Coated Tablet 1's
RXDRUG-DR-XY46121-1pc
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
Vocinti
Full Details
Dosage Strength
10mg
Drug Ingredients
- Vonoprazan
Drug Packaging
Film-Coated Tablet 1's
Generic Name
Vonoprazan
Dosage Form
Film-Coated Tablet
Registration Number
DR-XY46121
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
Gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration, or prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration.
Adjunct to Helicobacter pylori eradication in the followings: Gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early stage gastric cancer, or Helicobacter pylori gastritis.
Precautions for Indications: Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration: This drug should be administered to the patients who are under continuous administration of low-dose aspirin for prevention of blood clots and emboli formation. History of gastric ulcer or duodenal ulcer should be confirmed before starting administration.
Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration: This drug should be administered to the patients who are under continuous administration of NSAIDs for purpose such as pain management of rheumatoid arthritis or osteoarthritis, etc. History of gastric ulcer or duodenal ulcer should be confirmed before starting administration.
Adjunct to Helicobacter pylori eradication: The efficacy of Helicobacter pylori eradication in the advanced stage of gastric MALT lymphoma has not been established.
Helicobacter pylori eradication should be conducted in the idiopathic thrombocytopenic purpura patients only if Helicobacter pylori eradication is considered appropriate with referring to the guidelines etc.
The efficacy on the prevention of gastric cancer by Helicobacter pylori eradication has not been established other than the stomach after endoscopic resection of early stage gastric cancer.
It should be confirmed that Helicobacter pylori is positive and Helicobacter pylori gastritis should be diagnosed by endoscopy before starting administration for patients with Helicobacter pylori gastritis.
Adjunct to Helicobacter pylori eradication in the followings: Gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early stage gastric cancer, or Helicobacter pylori gastritis.
Precautions for Indications: Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration: This drug should be administered to the patients who are under continuous administration of low-dose aspirin for prevention of blood clots and emboli formation. History of gastric ulcer or duodenal ulcer should be confirmed before starting administration.
Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration: This drug should be administered to the patients who are under continuous administration of NSAIDs for purpose such as pain management of rheumatoid arthritis or osteoarthritis, etc. History of gastric ulcer or duodenal ulcer should be confirmed before starting administration.
Adjunct to Helicobacter pylori eradication: The efficacy of Helicobacter pylori eradication in the advanced stage of gastric MALT lymphoma has not been established.
Helicobacter pylori eradication should be conducted in the idiopathic thrombocytopenic purpura patients only if Helicobacter pylori eradication is considered appropriate with referring to the guidelines etc.
The efficacy on the prevention of gastric cancer by Helicobacter pylori eradication has not been established other than the stomach after endoscopic resection of early stage gastric cancer.
It should be confirmed that Helicobacter pylori is positive and Helicobacter pylori gastritis should be diagnosed by endoscopy before starting administration for patients with Helicobacter pylori gastritis.
Dosage/Direction for Use
Gastric ulcer, duodenal ulcer: Usually, for adults, a daily oral dose of 20 mg of Vonoprazan is administered once a day. For the treatment of gastric ulcer, the usual administration should be limited up to 8 weeks, and for duodenal ulcer, up to 6 weeks.
Reflux esophagitis: Usually, for adults, a daily oral dose of 20 mg of Vonoprazan is administered once a day. The usual administration should be limited up to 4 weeks. However, when the effect if insufficient, the drug may be administered up to 8 weeks. In addition, for the maintenance of healing of reflux esophagitis in patients who repeat recurrence and relapse of the condition, a daily oral dose of 10 mg is administered once a day, however, when the efficacy is inadequate, a daily oral dose of 20 mg may be administered once a day.
Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration: Usually, for adults, a daily oral dose of 10 mg of Vonoprazan is administered once a day.
Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration: Usually, for adults, a daily oral dose of 10 mg of Vonoprazan is administered once a day.
Adjunct to Helicobacter pylori eradication: Usually, for adults, the following 3 drugs are orally administered at the same time twice daily for 7 days: 20 mg/dose of Vonoprazan, 750 mg (potency)/dose as amoxicillin hydrate, and 200 mg (potency)/dose as clarithromycin. The dose of clarithromycin may be properly increased as the occasion demands, however, the upper limit is 400 mg (potency) twice daily.
When Helicobacter pylori eradication treatment with 3 drugs consist of a proton pump inhibitor, amoxicillin hydrate, and clarithromycin fails, alternative treatment with the following 3 drugs is given as follows; usually, for adults, 20 mg/dose of Vonoprazan, 750 mg (potency)/dose of amoxicillin hydrate, and 250 mg/dose of metronidazole are orally administered at the same time twice daily for 7 days.
Reflux esophagitis: Usually, for adults, a daily oral dose of 20 mg of Vonoprazan is administered once a day. The usual administration should be limited up to 4 weeks. However, when the effect if insufficient, the drug may be administered up to 8 weeks. In addition, for the maintenance of healing of reflux esophagitis in patients who repeat recurrence and relapse of the condition, a daily oral dose of 10 mg is administered once a day, however, when the efficacy is inadequate, a daily oral dose of 20 mg may be administered once a day.
Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration: Usually, for adults, a daily oral dose of 10 mg of Vonoprazan is administered once a day.
Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration: Usually, for adults, a daily oral dose of 10 mg of Vonoprazan is administered once a day.
Adjunct to Helicobacter pylori eradication: Usually, for adults, the following 3 drugs are orally administered at the same time twice daily for 7 days: 20 mg/dose of Vonoprazan, 750 mg (potency)/dose as amoxicillin hydrate, and 200 mg (potency)/dose as clarithromycin. The dose of clarithromycin may be properly increased as the occasion demands, however, the upper limit is 400 mg (potency) twice daily.
When Helicobacter pylori eradication treatment with 3 drugs consist of a proton pump inhibitor, amoxicillin hydrate, and clarithromycin fails, alternative treatment with the following 3 drugs is given as follows; usually, for adults, 20 mg/dose of Vonoprazan, 750 mg (potency)/dose of amoxicillin hydrate, and 250 mg/dose of metronidazole are orally administered at the same time twice daily for 7 days.
Overdosage
There is no experience of overdose with Vonoprazan.
Vonoprazan is not removed from the circulation by hemodialysis. If overdose occurs, treatment should be symptomatic and supportive.
Vonoprazan is not removed from the circulation by hemodialysis. If overdose occurs, treatment should be symptomatic and supportive.
Administration
May be taken with or without food.
Contraindications
Vonoprazan (Vocinti) tablets are contraindicated in the following patients: Patients with a history of hypersensitivity to any of the ingredients of this drug.
Patients who are receiving atazanavir sulphate or rilpivirine hydrochloride (see Interactions).
Patients who are receiving atazanavir sulphate or rilpivirine hydrochloride (see Interactions).
Special Precautions
Important Precautions: All indications: In the long-term treatment with this drug, close observation by such means as endoscopy should be made.
Reflux esophagitis: In the maintenance of healing, this drug should be administered only to the patients who repeat recurrence and recrudescence of the condition. Administration to the patients who do not necessitate maintenance of healing should be avoided. When the healing is maintained over a long period, and when there is no risk of recurrence, the dose reduction to a dose of 10 mg from a dose of 20 mg, or suspension of administration should be considered.
Other Precautions: In 2-year carcinogenicity studies in mice and rats, following observations were made: neuroendocrine tumors in the stomach with the similar exposure (AUC) at the clinical dose (20 mg/day) of vonoprazan, adenoma in the stomach (mouse) at the exposure approximately 300 times of the clinical exposure, and hepatic tumor at approximately more than 13 times (mouse) and approximately more than 58 times (rat) of the clinical exposure.
It has been reported that benign gastric polyp was observed in long-term administration of this drug.
The administration of Vonoprazan (Vocinti) tablets may mask the symptoms of gastric cancer. It is, therefore, necessary to ascertain the ulcer is not of a malignant nature before initiating the administration of this drug.
In several observational studies in overseas, an increased risk for osteoporosis-related fractures of the hip, wrist or spine under the treatment with proton pump inhibitors has been reported. The risk of fracture was especially increased in the patients receiving high dose or long term (a year or longer) treatment.
In several overseas observational studies, mainly in hospitalized patients, increased risk of gastrointestinal infection caused by Clostridium difficile was reported in patients who receive proton pump inhibitors.
Precautions Concerning Patients with Specific Backgrounds: Patients with Renal Impairment: A delay in the excretion of this drug may occur, which may result in an increase in the concentration of vonoprazan in blood.
Patients with Hepatic Impairment: A delay in the metabolism and excretion of this drug may occur, which may result in an increase in the concentration of vonoprazan in blood.
Use in Pregnancy: No clinical studies have been conducted to date to evaluate vonoprazan in subjects who are pregnant or lactating. This drug should be used in pregnant women or women having possibilities of being pregnant only if the expected therapeutic benefit is thought to outweigh any possible risk. In animal studies (rats), following exposure of more than approximately 28 times of the exposure (AUC) at the maximum clinical dose (40 mg/day) of vonoprazan, low values of fetal weight and placental weight, external abnormalities (anal stenosis and tail abnormalities) and visceral abnormalities (membranous ventricular septal defect and aberrant subclavian artery) were observed.
Use in Lactation: The continuation or discontinuation of breastfeeding should be considered while taking account of the expected therapeutic benefits of this drug and the benefits of maternal feeding. It has been reported in animal studies (rats) that vonoprazan is transferred to breast milk.
Use in Children: No clinical study has been conducted in pediatric patients.
Use in the Elderly: The physiological functions such as hepatic or renal function are decreased in elderly patients in general.
Reflux esophagitis: In the maintenance of healing, this drug should be administered only to the patients who repeat recurrence and recrudescence of the condition. Administration to the patients who do not necessitate maintenance of healing should be avoided. When the healing is maintained over a long period, and when there is no risk of recurrence, the dose reduction to a dose of 10 mg from a dose of 20 mg, or suspension of administration should be considered.
Other Precautions: In 2-year carcinogenicity studies in mice and rats, following observations were made: neuroendocrine tumors in the stomach with the similar exposure (AUC) at the clinical dose (20 mg/day) of vonoprazan, adenoma in the stomach (mouse) at the exposure approximately 300 times of the clinical exposure, and hepatic tumor at approximately more than 13 times (mouse) and approximately more than 58 times (rat) of the clinical exposure.
It has been reported that benign gastric polyp was observed in long-term administration of this drug.
The administration of Vonoprazan (Vocinti) tablets may mask the symptoms of gastric cancer. It is, therefore, necessary to ascertain the ulcer is not of a malignant nature before initiating the administration of this drug.
In several observational studies in overseas, an increased risk for osteoporosis-related fractures of the hip, wrist or spine under the treatment with proton pump inhibitors has been reported. The risk of fracture was especially increased in the patients receiving high dose or long term (a year or longer) treatment.
In several overseas observational studies, mainly in hospitalized patients, increased risk of gastrointestinal infection caused by Clostridium difficile was reported in patients who receive proton pump inhibitors.
Precautions Concerning Patients with Specific Backgrounds: Patients with Renal Impairment: A delay in the excretion of this drug may occur, which may result in an increase in the concentration of vonoprazan in blood.
Patients with Hepatic Impairment: A delay in the metabolism and excretion of this drug may occur, which may result in an increase in the concentration of vonoprazan in blood.
Use in Pregnancy: No clinical studies have been conducted to date to evaluate vonoprazan in subjects who are pregnant or lactating. This drug should be used in pregnant women or women having possibilities of being pregnant only if the expected therapeutic benefit is thought to outweigh any possible risk. In animal studies (rats), following exposure of more than approximately 28 times of the exposure (AUC) at the maximum clinical dose (40 mg/day) of vonoprazan, low values of fetal weight and placental weight, external abnormalities (anal stenosis and tail abnormalities) and visceral abnormalities (membranous ventricular septal defect and aberrant subclavian artery) were observed.
Use in Lactation: The continuation or discontinuation of breastfeeding should be considered while taking account of the expected therapeutic benefits of this drug and the benefits of maternal feeding. It has been reported in animal studies (rats) that vonoprazan is transferred to breast milk.
Use in Children: No clinical study has been conducted in pediatric patients.
Use in the Elderly: The physiological functions such as hepatic or renal function are decreased in elderly patients in general.
Use In Pregnancy & Lactation
Pregnant Women: No clinical studies have been conducted to date to evaluate vonoprazan in subjects who are pregnant or lactating. This drug should be used in pregnant women or women having possibilities of being pregnant only if the expected therapeutic benefit is thought to outweigh any possible risk. In animal studies (rats), following exposure of more than approximately 28 times of the exposure (AUC) at the maximum clinical dose (40 mg/day) of vonoprazan, low values of fetal weight and placental weight, external abnormalities (anal stenosis and tail abnormalities) and visceral abnormalities (membranous ventricular septal defect and aberrant subclavian artery) were observed.
Breast-feeding Women: The continuation or discontinuation of breastfeeding should be considered while taking account of the expected therapeutic benefits of this drug and the benefits of maternal feeding. It has been reported in animal studies (rats) that vonoprazan is transferred to breast milk.
Breast-feeding Women: The continuation or discontinuation of breastfeeding should be considered while taking account of the expected therapeutic benefits of this drug and the benefits of maternal feeding. It has been reported in animal studies (rats) that vonoprazan is transferred to breast milk.
Adverse Reactions
Gastric ulcer, duodenal ulcer, reflux esophagitis: Adverse reactions, including abnormalities in laboratory data, were observed in 186 (8.2%) of 2,271 patients who received once daily administration of 10 mg or 20 mg of Vonoprazan in the clinical trials performed before approval. The most common adverse reaction was constipation (0.7%).
Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration: Adverse reactions, including abnormalities in laboratory data, were observed in 73 (16.9%) of 431 patients who received once daily administration of 10 mg or 20 mg of Vonoprazan in the clinical trials performed before approval. The most common adverse reaction was constipation (1.9%).
Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration: Adverse reactions, including abnormalities in laboratory data, were observed in 78 (17.0%) of 460 patients who received once daily administration of 10 mg or 20 mg of Vonoprazan in the clinical trials performed before approval. The most common adverse reaction was constipation (1.5%).
Adjunct to Helicobacter pylori eradication in the case of gastric ulcer or duodenal ulcer: Adverse reactions, including abnormalities in laboratory data, were observed in 67 (20.4%) of 329 patients administered with Vonoprazan fumarate, amoxicillin and clarithromycin in the clinical trials before approval. The most common adverse reaction was diarrhea (10.6%).
Adjunct to Helicobacter pylori eradication in the case of gastric MALT lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early stage gastric cancer, or Helicobacter pylori gastritis: Concerning concomitant administration of vonoprazan fumarate, amoxicillin hydrate, and clarithromycin or metronidazole, no study such as clinical trials to determine the frequency of adverse reactions has been conducted.
With Vonoprazan fumarate, amoxicillin and metronidazole, adverse reactions including abnormalities in laboratory data were observed in 8 (16.0%) of 50 patients in the clinical trials before approval.
Following adverse reactions may occur. Therefore, close observation should be made, and if abnormality is observed, administration of this drug should be discontinued, and appropriate measures should be taken.
Clinically significant adverse reactions: All Indications: Pancytopenia, agranulocytosis, leukocytopenia, and thrombocytopenia (Frequency unknown).
Toxic epidermal necrolysis: TEN, Stevens-Johnson syndrome and erythema multiforme (Frequency unknown).
Adjunct to Helicobacter pylori eradication: Serious colitis accompanied with bloody stools, such as pseudomembranous colitis (Frequency unknown). If abdominal pain and frequent diarrhea occur, appropriate measures, such as immediate discontinuation of the treatment, should be taken. Serious colitis accompanied with bloody stools, such as pseudomembranous colitis may occur due to amoxicillin hydrate or clarithromycin being used for Helicobacter pylori eradication.
Hepatotoxicity: Hepatic function abnormalities including liver injury have been reported in clinical studies. Post marketing reports have also been received in patients treated with Vonoprazan, many of which occurred shortly after initiation of treatment. Discontinuation of Vonoprazan is recommended in patients who have evidence of liver function abnormalities or if they develop signs or symptoms suggestive of liver dysfunction.
Other adverse reactions: When the following adverse reactions are observed, appropriate measures should be taken according to the symptoms: (See Tables 3 and 4.)
Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration: Adverse reactions, including abnormalities in laboratory data, were observed in 73 (16.9%) of 431 patients who received once daily administration of 10 mg or 20 mg of Vonoprazan in the clinical trials performed before approval. The most common adverse reaction was constipation (1.9%).
Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration: Adverse reactions, including abnormalities in laboratory data, were observed in 78 (17.0%) of 460 patients who received once daily administration of 10 mg or 20 mg of Vonoprazan in the clinical trials performed before approval. The most common adverse reaction was constipation (1.5%).
Adjunct to Helicobacter pylori eradication in the case of gastric ulcer or duodenal ulcer: Adverse reactions, including abnormalities in laboratory data, were observed in 67 (20.4%) of 329 patients administered with Vonoprazan fumarate, amoxicillin and clarithromycin in the clinical trials before approval. The most common adverse reaction was diarrhea (10.6%).
Adjunct to Helicobacter pylori eradication in the case of gastric MALT lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early stage gastric cancer, or Helicobacter pylori gastritis: Concerning concomitant administration of vonoprazan fumarate, amoxicillin hydrate, and clarithromycin or metronidazole, no study such as clinical trials to determine the frequency of adverse reactions has been conducted.
With Vonoprazan fumarate, amoxicillin and metronidazole, adverse reactions including abnormalities in laboratory data were observed in 8 (16.0%) of 50 patients in the clinical trials before approval.
Following adverse reactions may occur. Therefore, close observation should be made, and if abnormality is observed, administration of this drug should be discontinued, and appropriate measures should be taken.
Clinically significant adverse reactions: All Indications: Pancytopenia, agranulocytosis, leukocytopenia, and thrombocytopenia (Frequency unknown).
Toxic epidermal necrolysis: TEN, Stevens-Johnson syndrome and erythema multiforme (Frequency unknown).
Adjunct to Helicobacter pylori eradication: Serious colitis accompanied with bloody stools, such as pseudomembranous colitis (Frequency unknown). If abdominal pain and frequent diarrhea occur, appropriate measures, such as immediate discontinuation of the treatment, should be taken. Serious colitis accompanied with bloody stools, such as pseudomembranous colitis may occur due to amoxicillin hydrate or clarithromycin being used for Helicobacter pylori eradication.
Hepatotoxicity: Hepatic function abnormalities including liver injury have been reported in clinical studies. Post marketing reports have also been received in patients treated with Vonoprazan, many of which occurred shortly after initiation of treatment. Discontinuation of Vonoprazan is recommended in patients who have evidence of liver function abnormalities or if they develop signs or symptoms suggestive of liver dysfunction.
Other adverse reactions: When the following adverse reactions are observed, appropriate measures should be taken according to the symptoms: (See Tables 3 and 4.)
Postmarketing: Following is a list of ADRs which have been observed in postmarketing and are not included as previously mentioned: (See Table 5.)
Drug Interactions
Vonoprazan (Vocinti) are metabolized mainly by hepatic drug-metabolizing enzyme CYP3A4 and partially by CYP2B6, CYP2C19 and CYP2D6.
Gastric antisecretory effect of Vonoprazan (Vocinti) tablets may promote or inhibit absorption of concomitant drugs. The use of Vonoprazan is therefore not recommended with some of these drugs for which absorption is dependent on acidic intragastric pH.
Contraindications for Co-administration: [Vonoprazan (Vocinti) tablets should not be co-administered with the following drugs.] (See Table 6.)
Gastric antisecretory effect of Vonoprazan (Vocinti) tablets may promote or inhibit absorption of concomitant drugs. The use of Vonoprazan is therefore not recommended with some of these drugs for which absorption is dependent on acidic intragastric pH.
Contraindications for Co-administration: [Vonoprazan (Vocinti) tablets should not be co-administered with the following drugs.] (See Table 6.)
Precautions for co-administration: [Vonoprazan (Vocinti) tablets should be administered with care when co-administered with the following drugs.] (See Table 7.)
Caution For Usage
Precautions Concerning Use: When dispensing the drug: The patient must be instructed to remove the tablets from the press-through package (PTP) before they are ingested. [It has been reported that, if the PTP sheet is swallowed, the sharp corners of the sheet may puncture the esophageal mucosa, and this could result in serious complications such as mediastinitis.]
Storage
Store at temperature not exceeding 30°C.
Action
Pharmacology: Mechanism of action: Vonoprazan does not require activation by acid and inhibits H+, K+-ATPase in a reversible and potassium-competitive manner. Vonoprazan has a strong basicity and resides on the acid production site of gastric parietal cells for a long time, thereby inhibiting gastric acid production. Vonoprazan exerts a strong inhibitory effect on formation of mucosal damage in upper part of the gastrointestinal tract. Vonoprazan does not exhibit anti-Helicobacter pylori activity nor inhibitory activity against Helicobacter pylori ureas.
Inhibiting activity on gastric acid secretion: Following consecutive administration of Vonoprazan at a dose of 10 mg or 20 mg in healthy adult male subjects for 7 days, proportions of the time exhibiting gastric pH of 4 or above within 24 hours were 63±9% and 83±17%, respectively.
Adjunctive effect on eradication of Helicobacter pylori: The role of Vonoprazan in the Helicobacter pylori eradication is considered to increase intragastric pH leading to the enhancement of antibacterial activity of amoxicillin hydrate, clarithromycin and metronidazole which are concomitantly administered.
Pharmacokinetics: Absorption: Effect of Foods: The following table shows pharmacokinetic parameters of Vonoprazan following single administration of Vonoprazan to healthy adult male subjects at 20 mg under fasting and after meal. Effect of food on pharmacokinetic was little observed. (See Table 1 and figure.)
Inhibiting activity on gastric acid secretion: Following consecutive administration of Vonoprazan at a dose of 10 mg or 20 mg in healthy adult male subjects for 7 days, proportions of the time exhibiting gastric pH of 4 or above within 24 hours were 63±9% and 83±17%, respectively.
Adjunctive effect on eradication of Helicobacter pylori: The role of Vonoprazan in the Helicobacter pylori eradication is considered to increase intragastric pH leading to the enhancement of antibacterial activity of amoxicillin hydrate, clarithromycin and metronidazole which are concomitantly administered.
Pharmacokinetics: Absorption: Effect of Foods: The following table shows pharmacokinetic parameters of Vonoprazan following single administration of Vonoprazan to healthy adult male subjects at 20 mg under fasting and after meal. Effect of food on pharmacokinetic was little observed. (See Table 1 and figure.)
Blood level: Pharmacokinetics at consecutive administration: At consecutive administration of a daily dose of 10 mg or 20 mg of Vonoprazan in healthy adult male subjects once daily for 7 days, AUC(0-tau) and Cmax increase as the dose increases. The degree of these increases is slightly higher than the dose ratio. It is considered that the steady state has been reached by day 3 of administration, since the trough level of the blood concentration of Vonoprazan is constant between day 3 and day 7 of administration. In addition, it is considered that pharmacokinetics of Vonoprazan at consecutive administration may not be time-dependent, as the result of the evaluation of accumulation with regard to AUC(0-tau) and T1/2 of Vonoprazan. The following table shows pharmacokinetic parameters of Vonoprazan on day 7 of administration. (See Table 2.)
Distribution: Protein binding rate: The protein binding rate is 85.2 to 88.0% when [14C] Vonoprazan in the range of 0.1 to 10 μg/mL is added to human plasma (in vitro).
Metabolism: Vonoprazan is metabolized mainly by hepatic drug-metabolizing enzyme CYP3A4 and partially by CYP2B6, CYP2C19 and CYP2D6. Vonoprazan is also metabolized by sulfotransferase SULT2A1 (in vitro).
Vonoprazan exhibits time-dependent inhibitory effect on CYP2B6, CYP2C19 and CYP3A4/5 (in vitro). In addition, Vonoprazan shows a slight concentration-dependent inductive effect on CYP1A2, but it shows little inductive effect on CYP2B6 and CYP3A4/5 (in vitro).
Excretion: When radioactive-labeled drug (15mg as Vonoprazan) is orally administered to non-Japanese healthy adult male subjects, 98.5% of the radioactivity administered is excreted into urine and feces by 168 hours after administration: 67.4% into urine and 31.1% into feces.
Patients with Specific Backgrounds: Pharmacokinetics in patients with hepatic disorders: The clinical trial conducted in abroad to evaluate the effect of hepatic disorders or pharmacokinetics in subjects with normal hepatic function and patients with mild (Child-Pugh score: A), moderate (Child-Pugh score: B), and severe (Child-Pugh score: C) hepatic disorder when administered with the drug as Vonoprazan 20 mg shows that AUC(0-inf) and Cmax were higher by 1.2 to 2.6 times and 1.2 to 1.8 times, respectively, in patient with mild, moderate and severe hepatic disorder, compared to subjects with normal hepatic function.
Pharmacokinetics in patients with renal disorders: The clinical trial conducted in abroad to evaluate the effect of renal disorders on pharmacokinetics of Vonoprazan in subjects with normal renal function (eGFR: ≥90 mL/min/1.73m2), patients with mild (eGFR: 60-89 mL/min/1.73m2), moderate (eGFR: 30-59 mL/min/1.73m2), and severe (eGFR: 15-29 mL/min/1.73m2) renal disorder and patients with end-stage renal disease (ESRD) (eGFR: <15 mL/min/1.73m2) when administered the drug as Vonoprazan 20 mg shows that AUC(0-inf) and Cmax were higher by 1.3 to 2.4 times and 1.2 to 1.8 times, respectively, in patients with mild, moderate and severe renal disorder compared to subjects with normal renal function. AUC(0-inf) and Cmax were higher by 1.3 times and 1.2 times, respectively, in ESRD patients compared to those in subjects with normal renal function.
Drug Interactions: Pharmacokinetics at concomitant administration of Vonoprazan and clarithromycin: The drug interaction study in non-Japanese healthy adult male subjects administered with single dose of Vonoprazan 40mg 30 minutes after breakfast on day 1 and day 8, and with repeated dose of clarithromycin 500 mg (potency) 2 times daily 30 minutes before breakfast and dinner on day 3-9, shows that AUC(0-inf) and Cmax of Vonoprazan when concomitantly administered with clarithromycin increased by 1.6 times and 1.4 times, respectively, compared to those of Vonoprazan when administered alone.
Pharmacokinetics at concomitant administration of Vonoprazan, amoxicillin hydrate and clarithromycin: The drug interaction study in healthy adult male subjects administered with twice daily of Vonoprazan 20 mg, amoxicillin hydrate 750 mg (potency) and clarithromycin 400 mg (potency) concomitantly for 7 days shows that no effect on pharmacokinetics of unchanged amoxicillin, however, AUC(0-12) and Cmax of Vonoprazan increased by 1.8 times and 1.9 times, respectively, and AUC(0-12) and Cmax of unchanged clarithromycin increased 1.5 times and 1.6 times, respectively.
Pharmacokinetics at concomitant administration of vonoprazan, low-dose aspirin or Vonoprazan, NSAIDs: The drug interaction study in healthy adult male subjects administered with Vonoprazan 40 mg and aspirin 100 mg or NSAID (loxoprofen sodium 60mg, diclofenac sodium 25 mg or meloxicam 10 mg) concomitantly showed no clear effect of low-dose aspirin or NSAIDs on pharmacokinetics of Vonoprazan and of Vonoprazan on pharmacokinetics of low-dose aspirin or NSAIDs.
Metabolism: Vonoprazan is metabolized mainly by hepatic drug-metabolizing enzyme CYP3A4 and partially by CYP2B6, CYP2C19 and CYP2D6. Vonoprazan is also metabolized by sulfotransferase SULT2A1 (in vitro).
Vonoprazan exhibits time-dependent inhibitory effect on CYP2B6, CYP2C19 and CYP3A4/5 (in vitro). In addition, Vonoprazan shows a slight concentration-dependent inductive effect on CYP1A2, but it shows little inductive effect on CYP2B6 and CYP3A4/5 (in vitro).
Excretion: When radioactive-labeled drug (15mg as Vonoprazan) is orally administered to non-Japanese healthy adult male subjects, 98.5% of the radioactivity administered is excreted into urine and feces by 168 hours after administration: 67.4% into urine and 31.1% into feces.
Patients with Specific Backgrounds: Pharmacokinetics in patients with hepatic disorders: The clinical trial conducted in abroad to evaluate the effect of hepatic disorders or pharmacokinetics in subjects with normal hepatic function and patients with mild (Child-Pugh score: A), moderate (Child-Pugh score: B), and severe (Child-Pugh score: C) hepatic disorder when administered with the drug as Vonoprazan 20 mg shows that AUC(0-inf) and Cmax were higher by 1.2 to 2.6 times and 1.2 to 1.8 times, respectively, in patient with mild, moderate and severe hepatic disorder, compared to subjects with normal hepatic function.
Pharmacokinetics in patients with renal disorders: The clinical trial conducted in abroad to evaluate the effect of renal disorders on pharmacokinetics of Vonoprazan in subjects with normal renal function (eGFR: ≥90 mL/min/1.73m2), patients with mild (eGFR: 60-89 mL/min/1.73m2), moderate (eGFR: 30-59 mL/min/1.73m2), and severe (eGFR: 15-29 mL/min/1.73m2) renal disorder and patients with end-stage renal disease (ESRD) (eGFR: <15 mL/min/1.73m2) when administered the drug as Vonoprazan 20 mg shows that AUC(0-inf) and Cmax were higher by 1.3 to 2.4 times and 1.2 to 1.8 times, respectively, in patients with mild, moderate and severe renal disorder compared to subjects with normal renal function. AUC(0-inf) and Cmax were higher by 1.3 times and 1.2 times, respectively, in ESRD patients compared to those in subjects with normal renal function.
Drug Interactions: Pharmacokinetics at concomitant administration of Vonoprazan and clarithromycin: The drug interaction study in non-Japanese healthy adult male subjects administered with single dose of Vonoprazan 40mg 30 minutes after breakfast on day 1 and day 8, and with repeated dose of clarithromycin 500 mg (potency) 2 times daily 30 minutes before breakfast and dinner on day 3-9, shows that AUC(0-inf) and Cmax of Vonoprazan when concomitantly administered with clarithromycin increased by 1.6 times and 1.4 times, respectively, compared to those of Vonoprazan when administered alone.
Pharmacokinetics at concomitant administration of Vonoprazan, amoxicillin hydrate and clarithromycin: The drug interaction study in healthy adult male subjects administered with twice daily of Vonoprazan 20 mg, amoxicillin hydrate 750 mg (potency) and clarithromycin 400 mg (potency) concomitantly for 7 days shows that no effect on pharmacokinetics of unchanged amoxicillin, however, AUC(0-12) and Cmax of Vonoprazan increased by 1.8 times and 1.9 times, respectively, and AUC(0-12) and Cmax of unchanged clarithromycin increased 1.5 times and 1.6 times, respectively.
Pharmacokinetics at concomitant administration of vonoprazan, low-dose aspirin or Vonoprazan, NSAIDs: The drug interaction study in healthy adult male subjects administered with Vonoprazan 40 mg and aspirin 100 mg or NSAID (loxoprofen sodium 60mg, diclofenac sodium 25 mg or meloxicam 10 mg) concomitantly showed no clear effect of low-dose aspirin or NSAIDs on pharmacokinetics of Vonoprazan and of Vonoprazan on pharmacokinetics of low-dose aspirin or NSAIDs.
MedsGo Class
Antacids, Antireflux Agents & Antiulcerants
Please sign in so that we can notify you about a reply